TP53 and cancer: MDM2 hyperactivity through mechanisms such as gene amplification, increased transcription and enhanced translation is observed in many human cancers harboring wild-type TP53 [5–7], and MDM2 overexpression has been suggested to act as an alternative mechanism of p53 inactivation, thus promoting tumor growth.